MBX Biosciences Inc [NASDAQ: MBX] jumped around 10.0 points on Monday, while shares priced at $20.0 at the close of the session, up 100.00%.
MBX Biosciences Inc stock is now -4.76% down from its year-to-date (YTD) trading value. MBX Stock saw the intraday high of $26.45 and lowest of $17.7665 per share. The company’s 52-week high price is 27.50, which means current price is +316.07% above from all time high which was touched on 09/22/25.
Compared to the average trading volume of 445.16K shares, MBX reached a trading volume of 28247756 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about MBX Biosciences Inc [MBX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MBX shares is $53.43 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MBX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for MBX Biosciences Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 15, 2025. While these analysts kept the previous recommendation, Mizuho raised their target price to Outperform. The new note on the price target was released on August 05, 2025, representing the official price target for MBX Biosciences Inc stock. Previously, the target price had yet another raise to $38, while Oppenheimer analysts kept a Outperform rating on MBX stock.
The Price to Book ratio for the last quarter was 3.06, with the Price to Cash per share for the same quarter was set at 6.69.
How has MBX stock performed recently?
MBX Biosciences Inc [MBX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 83.99. With this latest performance, MBX shares gained by 41.34% in over the last four-week period, additionally plugging by 153.49% over the last 6 months – not to mention a rise of 8.52% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MBX stock in for the last two-week period is set at 72.82, with the RSI for the last a single of trading hit 2.83, and the three-weeks RSI is set at 2.02 for MBX Biosciences Inc [MBX]. The present Moving Average for the last 50 days of trading for this stock 12.91, while it was recorded at 11.95 for the last single week of trading, and 12.10 for the last 200 days.
MBX Biosciences Inc (MBX) Capital Structure & Debt Analysis
According to recent financial data for MBX Biosciences Inc. ( MBX), the Return on Equity (ROE) stands at -56.28%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -52.32%, reflecting the company’s efficiency in generating profits from its assets. Additionally, MBX Biosciences Inc’s Return on Invested Capital (ROIC) is -35.05%, showcasing its effectiveness in deploying capital for earnings.
MBX Biosciences Inc (MBX) Efficiency & Liquidity Metrics
Based on MBX Biosciences Inc’s (MBX) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
MBX Biosciences Inc (MBX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, MBX Biosciences Inc. (MBX) effectively leverages its workforce, generating an average of -$1791162.79 per employee. The company’s liquidity position is robust, with a Current Ratio of 19.50% and a Quick Ratio of 19.50%, indicating strong ability to cover short-term liabilities.
Earnings analysis for MBX Biosciences Inc [MBX]
With the latest financial reports released by the company, MBX Biosciences Inc posted -2.78/share EPS, while the average EPS was predicted by analysts to be reported at -2.72/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.06. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MBX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for MBX Biosciences Inc go to 16.49%.
Insider trade positions for MBX Biosciences Inc [MBX]
There are presently around $109.78%, or 113.29%% of MBX stock, in the hands of institutional investors.
